Atlas Trials

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT02992522 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02992522
Sponsor
Beth Christian
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
B-Cell Lymphoma, UnspecifiedGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Marginal Zone LymphomaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaTransformed Recurrent Non-Hodgkin Lymphoma
Start date
2017-02-21
Primary completion
2026-08-15
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.